Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.

Autor: Cherniawsky HM; Division of Hematology, University of British Columbia, Vancouver, Canada., AlAhwal H; Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia., Mourad YA; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Forrest D; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Gerrie A; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Kuchenbauer F; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada; Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, Canada., Nantel SH; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Narayanan S; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Nevill T; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Power M; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Sanford D; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Toze C; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., White J; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Escano L; Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, Canada., Sutherland H; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada., Song K; Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada. Electronic address: ksong@bccancer.bc.ca.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Jul; Vol. 21 (7), pp. 476-482. Date of Electronic Publication: 2021 Mar 04.

The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.

Autor: Cherniawsky HM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Kukreti V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Reece D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Masih-Khan E; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Canadian Myeloma Research Group, Toronto, ON, Canada., McCurdy A; Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada., Jimenez-Zepeda VH; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada., Sebag M; Departments of Medicine and Oncology, Division of Hematology, McGill University, Montreal, QC, Canada., Song K; BC Cancer Agency, Vancouver General Hospital, Vancouver, BC, Canada., White D; Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, NS, Canada., Stakiw J; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada., LeBlanc R; Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, QC, Canada., Reiman A; Department of Oncology, Saint John Regional Hospital, Saint John, NB, Canada., Louzada M; London Regional Cancer Center, London, ON, Canada., Aslam M; Allan Blair Cancer Centre, Regina, SK, Canada., Kotb R; Cancer Care Manitoba, Winnipeg, MB, Canada., Gul E; Canadian Myeloma Research Group, Toronto, ON, Canada., Atenafu E; Canadian Myeloma Research Group, Toronto, ON, Canada., Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.

Publikováno v: European journal of haematology [Eur J Haematol] 2021 May; Vol. 106 (5), pp. 673-681. Date of Electronic Publication: 2021 Feb 16.